SRT3

226.1

+1.25%↑

ORNBV.FI

68.5

+3.4%↑

PHMA

95.6

-1.49%↓

DRW3

89.25

+3.42%↑

SRT3

226.1

+1.25%↑

ORNBV.FI

68.5

+3.4%↑

PHMA

95.6

-1.49%↓

DRW3

89.25

+3.42%↑

SRT3

226.1

+1.25%↑

ORNBV.FI

68.5

+3.4%↑

PHMA

95.6

-1.49%↓

DRW3

89.25

+3.42%↑

SRT3

226.1

+1.25%↑

ORNBV.FI

68.5

+3.4%↑

PHMA

95.6

-1.49%↓

DRW3

89.25

+3.42%↑

SRT3

226.1

+1.25%↑

ORNBV.FI

68.5

+3.4%↑

PHMA

95.6

-1.49%↓

DRW3

89.25

+3.42%↑

Home・Lista de Ações・Sanofi SA

Search

Sanofi SA

Fechado

SetorSaúde

74.69 0.77

Visão Geral

Variação de preço das ações

24h

Atual

Mín

73.695

Máximo

74.835

Indicadores-chave
By Trading Economics
Rendimento	-394M 1.6B
Vendas	-12B 11B
P/E Médio do Setor	20.158 49.8
EPS	1.34
Margem de lucro	14.354
Funcionários	74,846
EBITDA	1.5B 2.7B

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+20.42% upside

Dividendos
By Dow Jones
Próximos Ganhos	30 de jul. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-5.1B 94B
Abertura anterior	73.92
Fecho anterior	74.69

Sentimento de Notícias

By Acuity

31%

69%

101 / 347 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

91.3 / 96.1 Suporte e Resistência

Sanofi SA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

29 de abr. de 2026, 09:03 UTC

Ganhos

Spain's Santander Profit Climbs Amid Global Portfolio Reshuffle -- Update

29 de abr. de 2026, 05:27 UTC

Ganhos

Santander Books Jump in Profit on Top-Line Growth, Lower Costs

23 de abr. de 2026, 06:12 UTC

Ganhos

Sanofi Posts Higher Sales Amid Leadership Transition

1 de mai. de 2026, 06:14 UTC

Aquisições, Fusões, Aquisições de Empresas

Santander UK to Also Pay GBP213M Based on TSB's Tangible NAV

1 de mai. de 2026, 06:13 UTC

Aquisições, Fusões, Aquisições de Empresas

Santander UK Also Financed Deal From Funding by Parent, Banco Santander

1 de mai. de 2026, 06:12 UTC

Aquisições, Fusões, Aquisições de Empresas

Santander UK Financed Deal From Existing Cash Resources

1 de mai. de 2026, 06:08 UTC

Aquisições, Fusões, Aquisições de Empresas

Santander UK Announced Key Terms of Deal July 2025

1 de mai. de 2026, 06:03 UTC

Aquisições, Fusões, Aquisições de Empresas

Santander UK Buys TSB Banking for GBP2.65B

1 de mai. de 2026, 06:02 UTC

Aquisições, Fusões, Aquisições de Empresas

Santander UK Buys TSB Banking Group

29 de abr. de 2026, 12:01 UTC

Ganhos

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

29 de abr. de 2026, 06:27 UTC

Conversa de Mercado

Ganhos

Santander's Above-Forecast Earnings Should Be Well-Received -- Market Talk

29 de abr. de 2026, 04:55 UTC

Ganhos

Analysts Saw Santander 1Q Loan Loss Provisions EUR3.12B

29 de abr. de 2026, 04:55 UTC

Ganhos

Santander 1Q Loan Loss Provisions EUR3.225B

29 de abr. de 2026, 04:54 UTC

Ganhos

Analysts Saw Santander 1Q Operating Expenses EUR6.57B

29 de abr. de 2026, 04:54 UTC

Ganhos

Santander 1Q Operating Expenses EUR6.48B

29 de abr. de 2026, 04:52 UTC

Ganhos

Santander Backs 2028 View

29 de abr. de 2026, 04:52 UTC

Ganhos

Santander Backs 2026 View

29 de abr. de 2026, 04:52 UTC

Ganhos

Santander 1Q Underlying RoTE 15.2%

29 de abr. de 2026, 04:51 UTC

Ganhos

Santander End-1Q CET1 Ratio 14.4%

29 de abr. de 2026, 04:51 UTC

Ganhos

Analysts Saw Santander 1Q Net Interest Income EUR10.86B

29 de abr. de 2026, 04:51 UTC

Ganhos

Santander 1Q Net Interest Income EUR11.02B

29 de abr. de 2026, 04:50 UTC

Ganhos

Analysts Saw Santander 1Q Underlying Net Pft EUR3.47B

29 de abr. de 2026, 04:50 UTC

Ganhos

Santander 1Q Underlying Pft EUR3.56B

29 de abr. de 2026, 04:49 UTC

Ganhos

Santander 1Q Net Pft EUR5.455B

29 de abr. de 2026, 04:49 UTC

Ganhos

Analysts Saw Santander 1Q Rev EUR15.00B

29 de abr. de 2026, 04:49 UTC

Ganhos

Santander 1Q Rev EUR15.14B

27 de abr. de 2026, 09:32 UTC

Conversa de Mercado

Ganhos

Sanofi's Dupixent Sales Growth Set to Moderate -- Market Talk

27 de abr. de 2026, 09:19 UTC

Conversa de Mercado

Sanofi's New CEO Needs to Be Clear on Strategy -- Market Talk

23 de abr. de 2026, 05:34 UTC

Ganhos

Sanofi: 2026 Expectations Are at Constant Exchange Rates

23 de abr. de 2026, 05:34 UTC

Ganhos

Sanofi Sees Business EPS Growth Slightly Faster Than Sales in 2026

Comparação entre Pares

Variação de preço

Sanofi SA Previsão

Preço-alvo

By TipRanks

20.42% parte superior

Previsão para 12 meses

Média 93.701 EUR 20.42%

Máximo 107 EUR

Mínimo 80 EUR

Com base em 10 analistas de Wall Street que oferecem metas de preço de 12 meses para Sanofi SA - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

10 ratings

4

Comprar

6

Manter

0

Vender

Com base em 10 analistas que deram avaliações de ações para Sanofi SA - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

91.3 / 96.1Suporte e Resistência

Recent bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Sentimento

By Acuity

101 / 347 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Outras ações do setor

SRT3

Sartorius AG

226.1

ORNBV.FI

Orion Oyj (Class B)

68.5

PHMA

Pharma Mar SA

95.6

DRW3

Draegerwerk AG & Co KGaA- PREF

89.25

Live chat